Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD'
Tweet Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
